Silence Therapeutics (SLN) Invested Capital: 2019-2025
Historic Invested Capital for Silence Therapeutics (SLN) over the last 3 years, with Sep 2025 value amounting to $74.1 million.
- Silence Therapeutics' Invested Capital fell 41.54% to $74.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $74.1 million, marking a year-over-year decrease of 41.54%. This contributed to the annual value of $134.0 million for FY2024, which is 509.39% up from last year.
- Silence Therapeutics' Invested Capital amounted to $74.1 million in Q3 2025, which was down 21.34% from $94.2 million recorded in Q2 2025.
- In the past 5 years, Silence Therapeutics' Invested Capital ranged from a high of $156.8 million in Q1 2024 and a low of $5.4 million during Q1 2022.
- In the last 3 years, Silence Therapeutics' Invested Capital had a median value of $103.4 million in 2025 and averaged $92.6 million.
- In the last 5 years, Silence Therapeutics' Invested Capital soared by 677.38% in 2024 and then crashed by 41.54% in 2025.
- Quarterly analysis of 5 years shows Silence Therapeutics' Invested Capital stood at $11.5 million in 2021, then surged by 125.26% to $25.9 million in 2022, then decreased by 15.05% to $22.0 million in 2023, then skyrocketed by 509.39% to $134.0 million in 2024, then plummeted by 41.54% to $74.1 million in 2025.
- Its Invested Capital was $74.1 million in Q3 2025, compared to $94.2 million in Q2 2025 and $112.7 million in Q1 2025.